Helping You Build Wealth With Honest Research
Since 1996. Read On...

MEMBER'S LOGIN

MEMBER'S LOGINX

     
Invalid Username / Password
   
     
   
     
 
Invalid Captcha
   
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

Revealed
India's Third Giant Leap

This Could be One of the Biggest Opportunities for Investors




Important: We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
By submitting your email address, you also sign up for Profit Hunter, a daily newsletter from Equitymaster
covering exciting investing ideas and opportunities in India.

AD

FMCG stocks on a tear!
Fri, 24 Sep 01:30 pm

Persistent buying activity led the Indian markets to rise higher into the positive territory during the previous two hours of trade. Currently stocks from the consumer durables, realty and FMCG spaces are amongst the top gainers, while those from the IT and metal indices are the top underperformers. The market sentiment is optimistic as there are 1.8 gainers for every loser on the overall BSE.

The BSE-Sensex is trading higher by around 110 points (up 0.6%), while the NSE-Nifty is up by about 35 points (up 0.6%). Stocks from the small and midcap spaces are however seeing more interest as the BSE-Midcap and BSE-Smallcap indices are trading higher by 0.8% and 1.0% respectively. The rupee is trading at 45.52 to the US dollar.

Stocks of pharmaceutical companies are currently trading firm led by Dishman Pharma, Biocon and Ipca Labs. The stock of Aurobindo Pharma is also trading firm on news of the company receiving final approvals from the US health regulator, the US FDA (Food and Drug Administration), to sell its generic 'Ampicillin' and 'Sulbactam' for injections in multiple strengths. The FDA is believed to have approved three Abbreviated New Drug Applications (ANDA) for these injections. These are used to treat skin infections, abdominal and gynecological infections. The Ampicillin and Sulbactam for injection is a generic version of Pfizer's drug ‘Unasyn’, which is believed to have a market size of US$ 50 m (approximately Rs 2.3 bn) as of June 2009. This is a positive for the company and will enable it to bolster revenues from the highly competitive US generics market.

FMCG stocks have seen a sharp increase in price over the last few days with the BSE-FMCG index registering an increase of about 10% in the last 30 days. In fact, heavy weights like HUL and ITC have grown even fast, registering a growth of over 12.5% and over 10.5% respectively during the same period.

One of the reasons for this has been the recent price hikes taken the industry as a whole to protect margins. Another reason is that the BSE-FMCG index had been an under performer over the past year due to high valuations of FMCG companies. However, the recent FII funds entering the country have seen investing into this sector as a hedge against their other investments thereby pushing up the valuations further.

For information on how to pick stocks that have the potential to deliver big returns, download our special report now!

View all commentaries | Archives

Read the latest Market Commentary


Equitymaster requests your view! Post a comment on "FMCG stocks on a tear!". Click here!

  
ABOUT EQUITYMASTER

Since 1996, Equitymaster has been the source for honest and credible opinions on investing in India. With solid research and in-depth analysis Equitymaster is dedicated towards making its readers- smarter, more confident and richer every day. Here's why hundreds of thousands of readers spread across more than 70 countries Trust Equitymaster.

PREMIUM PRODUCTS
QUICK LINKS
POPULAR TOPICS
TRENDING TOPICS
FREE NEWSLETTERS
EQUITYMASTER SUPPORTS
  • HelpYourNGO
  • You Tube
  • Linkedin
  • Twitter
  • Telegram
  • Google Play

Copyright © Equitymaster Research Private Limited (formerly Equitymaster Agora Research Private Limited).

Whitelist | Refer | Terms | Privacy | Contact | About | Sitemap

Phone +91-9136015013

Equitymaster Research Private Limited (formerly Equitymaster Agora Research Private Limited) (Research Analyst)
SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.

103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Email: info@equitymaster.com. Website: www.equitymaster.com.
CIN:U74999MH2007PTC175407

Name of the Compliance & Grievance Officer: Ms Sonal Ramachandran
Telephone: +91-22-61434003 | Email: compliance@equitymaster.com

LEGAL DISCLAIMER:
Investment in securities market are subject to market risks. Read all the related documents carefully before investing.
Registration granted by SEBI and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

All rights reserved. Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.

Equitymaster Research Private Limited (formerly Equitymaster Agora Research Private Limited) (Research Analyst) bearing Registration No. INH000000537 (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA, Canada or the European Union countries, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.